TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Akari Therapeutics Releases New CEO Corner Segment Highlighting 2025 Progress and Path to Clinical Transition In 2026

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Not Specified
Akari Therapeutics Releases New CEO Corner Segment Highlighting 2025 Progress and Path to Clinical Transition In 2026

Akari Therapeutics announced progress in 2025 and outlined its path toward clinical transition in 2026. The company established a manufacturing partnership with WuXi Biologics and initiated pre-filing activities, with plans to launch its First-in-Human clinical trial by late 2026/early 2027. The company's lead candidate AKTX-101 is an ADC targeting Trop2 with a novel PH1 spliceosome-modulating payload designed to deliver dual mechanisms of action: direct tumor cytotoxicity and immune activation.

Insights
CGEMY   neutral

Mentioned as part of Delaporte's professional background, with no direct impact on current business performance


AKTX   positive

Company achieved key milestones in 2025 including manufacturing partnership with WuXi Biologics, initiated CMC activities, and is on track for clinical trial initiation by late 2026/early 2027. Preclinical data shows promising efficacy and safety profile for lead candidate AKTX-101 with potential synergy with checkpoint inhibitors.